OncoDNA is a company specializing in precision for the treatment of cancer and other genetic diseases. We are a group of passionate people who have developed a unique portfiolio of smart and personalized solutions to help you see clear through molecular complexity. You can rely on our extensive expertise in genomics and theranostics to collect, explore and interpret the tons of complex data that you need for your research project, clinical trials or clinical decision-making. Together, we can bring therapeutic innovation to the clinics and deliver the best of care to patients.
We are dedicated to helping you drive innovation in cancer and genetic diseases. Through a variety of NGS, molecular profiling and data interpretation services, we can deliver the robust, accurate and reliable data that you need to conduct research projects in a rapid and cost-efficient manner.
Our services focus on helping you to accelerate drug development by providing valuable and high-quality molecular insights in a fast turnaround time to fully characterize a patient, facilitate patient matching to clinical trials and monitor therapeutic response in real time.
Treating late stage tumors or cancer of unknown primary can be challenging. Our biomarker testing solutions are designed to help you spot the molecular weaknesses of an individual cancer, predict resistance to therapies, identify the most effective treatment options and monitor your patient's response to therapy in real time.
Our biomarker tests help physicians and their patients to understand the molecular particularities of an individual tumor, match their patients with the most effective chemotherapy, immunotherapy, targeted therapy, hormone therapy or clinical trial options, as well as to monitor their disease progression and therapeutic response. The tests are performed on tissue sample or liquid biopsy and are available for advanced, metastatic solid tumors.
Unique combination of DNA, RNA and protein analyses on a tumor tissue to support clinical decisions at diagnosis or disease progression.
Fast and minimally invasive analysis of cancer-specific genomic panels for lung, colorectal and breast cancer patients.
Analysis of ctDNA to monitor tumor progression in real time and detect lack of response or resistance to treatment as soon as it appears.
IntegraGen is an OncoDNA group company specializing in the genomics of cancer and rare genetic diseases. Backed by highly competent and qualified teams, IntegraGen is a leading player in genomic services which has been operating sequencing platforms for research institutes of excellence.
Exome, whole genome and custom gene panel sequencing services for cancer and rare diseases.
RNA sequencing services to precisely measure transcriptome expression in tissue samples or liquid biopsies.
Cost-effective and high-throughput services to analyze genome-wide methylation profiles.
Cost-effective and flexible services to interrogate 10’s to millions SNP markers in a timely manner.
We have developed a complete portfolio of secure online platforms to help you analyze your sequencing data quickly and easily, match them with the latest therapies in oncology, build personalized reports and engage with a community of healthcare professionals.
Secured interface reporting the clinical recommendations resulting from our biomarker tests and connecting you with other cancer professionals.
Interactive platform that transforms the raw NGS data coming from your lab into clear clinical guidance for late stage cancer patients.
User-friendly interface to quickly and intuitively analyze DNA and RNA sequencing data from tumor samples, including FFPE and cf-DNA.
Intuitive app for the dynamic exploration of RNA sequencing data, enabling navigation intro expression profile, immediate analysis, annotations and data exportation.
Tailored consulting and support for an advanced biostatistical and bioinformatic analysis of genomic data ranging from the initial design of genomic research projects to the detailed evaluation of research results.
Cloud-based app for a tailored and in-depth analysis of the whole genome, whole exome and gene panel sequencing data when exploring genetic diseases.
Given the expertise of OncoDNA in delivering solutions in precision medicine, we initiated this collaboration with enthusiasm with the aim of developing a specific SOLTI OncoKDM solution integrating any kind of molecular data that might reveal unappreciated vulnerabilities in the tumours of AGATA patients, allowing us to tailor much better their treatment options.
Compared to its competitors, OncoKDM includes patient-centred features that enable oncologists to recommend and make the right treatment decisions according to patient's data and medical history. Moreover, OncoKDM is user-friendly and easy to use, another advantage!